English Language Quiz For Bank Mains Exam 2024-22nd January

Directions (1-5): Given below are six sentences (A) (B) (C) (D) (E) (F) and (G). Answer the following questions after rearranging the following sentences into a coherent paragraph along with the identification of the incoherent sentence.

(A)The Act allows seven years of market exclusivity and financial incentives to innovators of these drugs.
(B)Privileges under the Act may be conferred to companies for drugs to treat a disease that affect less than 200,000 people in the U.S., or for a disease that affects more than 200,000 people but for which there is no hope of recouping R&D costs.
(C)As a result of this exclusivity, orphan drugs are often exorbitantly priced.
(D)The idea is that without these incentives, companies would find it difficult to recoup their R&D costs given the small number of people suffering from the rare disease.
(E) Gilead stated that it had transitioned to an “expanded access” programme, for emergency use in severely ill patients.
(F)In the U.S., under the Orphan Drug Act, 1983, companies are provided incentives to develop therapies, or orphan drugs, for rare diseases.
(G)Interestingly, according to the regulations for revocation, if the number of people suffering from the disease exceeds 200,000 after designation but before approval, this would not be a ground for revocation.

Q1. If sentence (A) “The Act allows seven years of market exclusivity and financial incentives to innovators of these drugs.” , is the THIRD sentence of the coherent paragraph, then which of the following sentences doesn’t fit into the paragraph, formed after rearranging other sentences?

(a) C
(b) F
(c) D
(d) E
(e) B

Q2. Which of the following pairs fall correctly as it is in the final coherent sequence of the sentences, formed after rearrangement?
(a) C-B
(b) B-E
(c) A-D
(d) C-E
(e) E-D

Q3. If sentence (A) “The Act allows seven years of market exclusivity and financial incentives to innovators of these drugs.”, is the THIRD sentence of the coherent paragraph, identify the correct sequence of the sentences to form a coherent paragraph (excluding the incoherent one)?
(a) FEACBG
(b) FDACBG
(c) FADECG
(d) FDACGB
(e) FEACDB

Q4. Considering the sentence (A) “The Act allows seven years of market exclusivity and financial incentives to innovators of these drugs.”, is the THIRD sentence of the coherent paragraph, which of the following statement should be the FIFTH sentence after the rearrangement (excluding the incoherent sentence)?
(a) B
(b) A
(c) F
(d) D
(e) C

Q5. Considering the sentence, the sentence (A) “The Act allows seven years of market exclusivity and financial incentives to innovators of these drugs.”, is the THIRD sentence of the coherent paragraph, which of the following statement should be the SECOND sentence after the rearrangement (excluding the incoherent sentence)?
(a) F
(b) B
(c) E
(d) C
(e) D

Solutions

S1. Ans. (d)
Sol. The correct sequence is FDACBG.
(F)In the U.S., under the Orphan Drug Act, 1983, companies are provided incentives to develop therapies, or orphan drugs, for rare diseases.
(D)The idea is that without these incentives, companies would find it difficult to recoup their R&D costs given the small number of people suffering from the rare disease.
(A)The Act allows seven years of market exclusivity and financial incentives to innovators of these drugs.
(C)As a result of this exclusivity, orphan drugs are often exorbitantly priced.
(B)Privileges under the Act may be conferred to companies for drugs to treat a disease that affect less than 200,000 people in the U.S., or for a disease that affects more than 200,000 people but for which there is no hope of recouping R&D costs.
(G)Interestingly, according to the regulations for revocation, if the number of people suffering from the disease exceeds 200,000 after designation but before approval, this would not be a ground for revocation.

S2. Ans. (a)
Sol. The correct sequence is FDACBG.
(F)In the U.S., under the Orphan Drug Act, 1983, companies are provided incentives to develop therapies, or orphan drugs, for rare diseases.
(D)The idea is that without these incentives, companies would find it difficult to recoup their R&D costs given the small number of people suffering from the rare disease.
(A)The Act allows seven years of market exclusivity and financial incentives to innovators of these drugs.
(C)As a result of this exclusivity, orphan drugs are often exorbitantly priced.
(B)Privileges under the Act may be conferred to companies for drugs to treat a disease that affect less than 200,000 people in the U.S., or for a disease that affects more than 200,000 people but for which there is no hope of recouping R&D costs.
(G)Interestingly, according to the regulations for revocation, if the number of people suffering from the disease exceeds 200,000 after designation but before approval, this would not be a ground for revocation.

S3. Ans. (b)
Sol. The correct sequence is FDACBG.
(F)In the U.S., under the Orphan Drug Act, 1983, companies are provided incentives to develop therapies, or orphan drugs, for rare diseases.
(D)The idea is that without these incentives, companies would find it difficult to recoup their R&D costs given the small number of people suffering from the rare disease.
(A)The Act allows seven years of market exclusivity and financial incentives to innovators of these drugs.
(C)As a result of this exclusivity, orphan drugs are often exorbitantly priced.
(B)Privileges under the Act may be conferred to companies for drugs to treat a disease that affect less than 200,000 people in the U.S., or for a disease that affects more than 200,000 people but for which there is no hope of recouping R&D costs.
(G)Interestingly, according to the regulations for revocation, if the number of people suffering from the disease exceeds 200,000 after designation but before approval, this would not be a ground for revocation.

S4. Ans. (a)
Sol. The correct sequence is FDACBG.
(F)In the U.S., under the Orphan Drug Act, 1983, companies are provided incentives to develop therapies, or orphan drugs, for rare diseases.
(D)The idea is that without these incentives, companies would find it difficult to recoup their R&D costs given the small number of people suffering from the rare disease.
(A)The Act allows seven years of market exclusivity and financial incentives to innovators of these drugs.
(C)As a result of this exclusivity, orphan drugs are often exorbitantly priced.
(B)Privileges under the Act may be conferred to companies for drugs to treat a disease that affect less than 200,000 people in the U.S., or for a disease that affects more than 200,000 people but for which there is no hope of recouping R&D costs.
(G)Interestingly, according to the regulations for revocation, if the number of people suffering from the disease exceeds 200,000 after designation but before approval, this would not be a ground for revocation.

S5. Ans. (e)
Sol. The correct sequence is FDACBG.
(F)In the U.S., under the Orphan Drug Act, 1983, companies are provided incentives to develop therapies, or orphan drugs, for rare diseases.
(D)The idea is that without these incentives, companies would find it difficult to recoup their R&D costs given the small number of people suffering from the rare disease.
(A)The Act allows seven years of market exclusivity and financial incentives to innovators of these drugs.
(C)As a result of this exclusivity, orphan drugs are often exorbitantly priced.
(B)Privileges under the Act may be conferred to companies for drugs to treat a disease that affect less than 200,000 people in the U.S., or for a disease that affects more than 200,000 people but for which there is no hope of recouping R&D costs.
(G)Interestingly, according to the regulations for revocation, if the number of people suffering from the disease exceeds 200,000 after designation but before approval, this would not be a ground for revocation.